THE GLOBAL IMMUNOGLOBULINS MARKET SIZE WAS VALUED AT USD 13.59 BILLION IN 2020 AND IS EXPECTED TO REACH USD 21.58 BILLION BY 2026, GROWING AT A CAGR OF 8.01% DURING THE FORECAST PERIOD

Global Immunoglobulins Market Size, Share, Trends Analysis Report by Product (Intravenous Immunoglobulin, Subcutaneous Immunoglobulin, & Intramuscular Immunoglobulin) By Application (Primary Immunodeficiency, Chronic Immune Deficiency Polyradiculoneuropathy, Secondary Immunodeficiency, Immune Thrombocytopenic Purpura, Myasthenia Gravis, and Others), By End User (Hospital & Clinic, Homecare), By Geography (North America, Europe, APAC, Latin America, Middle East & Africa) Industry Analysis Report Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2021–2026

GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

262 Pages

105 Tables

125 Charts

5 Regions

18 Countries

13 Companies

4 Market Segment

IMMUNOGLOBULINS MARKET REPORT SCOPE

Report Attribute Details
MARKET SIZE (REVENUE) USD 21.58 Billion USD (2026)
CAGR 8.01% (2021-2026)
BASE YEAR 2020
FORECAST YEAR 2021-2026
MARKET SEGMENTS By Product (Intravenous Immunoglobulin, Subcutaneous Immunoglobulin, & Intramuscular Immunoglobulin) By Application (Primary Immunodeficiency, Chronic Immune Deficiency Polyradiculoneuropathy, Secondary Immunodeficiency, Immune Thrombocytopenic Purpura, Myasthenia Gravis, and Others), By End User (Hospital & Clinic, Homecare)
GEOGRAPHIC ANALYSIS North America, Europe, APAC, Latin America, Middle East & Africa
COUNTRIES COVERED US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, Turkey

MARKET OVERVIEW

The global immunoglobulins market was valued at USD 13.5 Billion in 2020 and is expected to reach USD 21.58 Billion by 2026, growing at a CAGR of 8.01% during the forecast period. The pandemic has had and continues to have a major impact on the plasma derivatives industry. It contributed to the increase in the cost/liter of collected plasma due to the increased donor fees and increased incidence of a fixed cost of centers with respect to the lower volumes collected. The recent developments and the increasing scope of immunoglobulin products in treating numerous rare and autoimmune diseases have increased the growth rate for the immunoglobulin industry.

KEY HIGHLIGHTS

  • The price of immunoglobulin increased by around 5% in Europe and by 6% in the US.
  • With the increasing outcome of the fractionation and the challenge of plasma shortage, the technological and scientific developments in the field of plasma fractionation are expected to drive the market of immunoglobins.
  • Immunoglobulins dominate the industry of plasma-derived products. This share is largely attributed to the increasing demand resulting from developed ways of diagnosing autoimmune diseases.
  • The major challenge for the immunoglobulin industry is to maintain the balance between supply and demand. As the immunoglobulin products require blood plasma, the production value is limited by the quantity of plasma collected.
  • Partnerships with the official plasma collection agencies of the country have propelled the growth of many vendors.

SEGMENTATION ANALYSIS

  • Intravenous immunoglobulins (IVIG) are the most used form of immunoglobulin to manage autoimmune diseases and immunodeficiency. Since the proposed therapeutic use of immunoglobulins, it is being administered through the intravenous route, which provides maximum bioavailability and maximum efficacy.
  • The market is led by primary immunodeficiency, which acquired 26.05% of the global immunoglobulins market in 2020. The symptoms of primary immunodeficiencies are frequent pneumonia, baronial infections, sinus infection, skin infections, meningitis, inflammation, low platelet count, etc.
  • The largest immunoglobulins market share based on end-users is acquired by the hospital and clinic segment. The home care segment is expected to grow faster because of the increasing demand for home healthcare services.

GEOGRAPHICAL ANALYSIS

  • North America acquired a 46.00% share of the global immunoglobulins market in 2020. This is attributed to many factors such as higher awareness towards personal health, a patient-centric healthcare system, advancements in healthcare, higher throughput of plasma collection centers, leading global vendors being native to the industry, etc.
  • Europe is the second-largest market for immunoglobulin products because of its higher demand compared to other regions. The region has a higher awareness and highly regulated market, which enables safe blood and plasma collection practices.
  • APAC is considered an emerging industry for immunoglobulin products, which are needed for treating autoimmune disorders. China is leading the APAC immunoglobulins market. The Chinese population has a higher awareness of blood donation and its possible use in manufacturing life-saving products.

VENDOR ANALYSIS

  • The key players in the immunoglobulins industry are Takeda Pharmaceutical, CSL Limited, Grifols, S.A, Kendrion Biopharma, and Octapharma AG.
  • The global immunoglobulins industry is dominated by mainly three vendors, CSL Limited, Takeda Pharmaceutical Company Limited, and Grifols S.A. They share a highly competitive environment, where each competes in terms of newer product launches and regulatory approval for those and existing products.
  • For new vendors, emerging markets and low-resource countries are ideal markets, as they have a higher population and greater inclination towards donating blood or plasma in compensation.
  • For the vendors in the immunoglobulins industry, it is crucial to procure the plasma for fractionation. It can be done through wide installations of plasma collection centers across the countries, allowing the collection of higher volumes of plasma.
  • Partnerships with the official plasma collection agencies of the country have propelled the growth of many vendors. Many new vendors have been benefitted from such partnerships.


The global immunoglobulins market research report includes an in-depth analysis of the industry analysis with market dynamics, competitive landscape, drivers, and restraints for the following segments

By Product

  • Intravenous Immunoglobulin
  • Subcutaneous Immunoglobulin
  • Intramuscular Immunoglobulin

By Application

  • Primary Immunodeficiency
  • Chronic Immune Deficiency Polyradiculoneuropathy
  • Secondary Immunodeficiency
  • Immune Thrombocytopenic Purpura
  • Myasthenia Gravis
  • Others

By End User

  • Hospital & Clinic
  • Homecare

By Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
  • APAC
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Turkey

Frequently Asked Questions

The global immunoglobulins market was valued at USD 13.59 billion in 2020 and is expected to reach USD 21.58 billion by 2026.
The key trends are developments in the plasma Fractionation Process, immunoglobulins in homecare, and recent regulatory approvals for immunoglobulin.
North America region accounted for the largest Immunoglobulins Market share.
The key players are Takeda Pharmaceutical, CSL Limited, Grifols, S.A, Kendrion Biopharma, and Octapharma AG
The factors driving the immunoglobulins market are the impact of the use of IVIg during transplant and self-sufficiency programs for plasma-derived medicinal products.
Download Free Sample
Read More

Select a license type that suits your business needs

Single User Licence
$3750.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5 User Licence
$4250.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
$5250.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Select a license type that suits your business needs

Best Value Tag
Coming Soon
  • Stay tuned with us.

YOU CAN GET A FREE SAMPLE OF THIS REPORT!

Fill out your details & get your free sample

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Our Clients

Licence Types What are these?

Our Clients Speak

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date